Objective: To investigate the PSA level of 16 222 asymptematic men in Shenzhen who came from different areas of China, in order to find out the PSA levels of Chinese men.
Methods: Serum samples of 16 222 men who came to Peking University Shenzhen Hospital for health examination were collected, all of whom had no symptoms. Their serum PSA levels were measured with MEIA with ILMA instrument.
Results: The mean PSA level of the 16 222 men in our research was 0.986 μg/L, and the standard deviation was 1.190. The 95% percentile was 2.375 μg/L. Of all the cases ,the 95% percentile of 15 498 was lower than 2.5 μg/L, about 95.472%;that of 699 was between 2.5-10.0 μg/L, about 4.306%;And if took 4.0 μg/L as reference value,that of 15 948 cases was below 4.0 μg/L, about 98.244%;that of 249 was between 4.0-10.0 μg/L, about 1.534%;That of only 36 cases was greater than 10.0 μg/L, about 0.222%;The 95% percentiles of the different age groups were: 10-19 years 0-1.067 μg/L;20-29 years 0-1.818 μg/L;30-39 years 0-1.914 μg/L;40-49 years 0-2.001 μg/L;50-59 years 0-2.900 μg/L;60-69 years 0-5.862 μg/L;70-79 years 0-8.536 μg/L;elder than 80 years 0-12.869 μg/L;There were statistic differences between thedifferent age groups.
Conclusion: Our data demonstrate that the mean value of PSA levels of Chinese men is 0.986 μg/L at present stage, and the 95% percentile is 2.375 g/L. Our PSA levels of each age group are different from Oesterling's reference values which are commonly accepted in the world. The PSA level of Chinese men who are under 60 years is lower than that of Euramericans, while the PSA level of Chinese men who are above 60 years is higher than that of Euramericans. This shows that for the men who are under 60 the reference value should be 2.5 μg/L, while for the men who are above 60, we could still use 4 μg/L as reference value.
Download full-text PDF |
Source |
---|
Neural Netw
January 2025
Key Laboratory of Smart Manufacturing in Energy Chemical Process, Ministry of Education, East China University of Science and Technology, Shanghai 200237, China; Center of Intelligent Computing, School of Mathematics, East China University of Science and Technology, Shanghai 200237, China. Electronic address:
Event-related potentials (ERPs) can reveal brain activity elicited by external stimuli. Innovative methods to decode ERPs could enhance the accuracy of brain-computer interface (BCI) technology and promote the understanding of cognitive processes. This paper proposes a novel Multi-Scale Pyramid Squeeze Attention Similarity Optimization Classification Neural Network (MS-PSA-SOC) for ERP Detection.
View Article and Find Full Text PDFScand J Urol
January 2025
Department of Urology, Odense University Hospital, Odense, Denmark; Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Objective: Early and accurate diagnosis of prostate cancer (PC) is crucial for effective treatment. Diagnosing clinically insignificant cancers can lead to overdiagnosis and overtreatment, highlighting the importance of accurately selecting patients for further evaluation based on improved risk prediction tools. Novel biomarkers offer promise for enhancing this diagnostic process.
View Article and Find Full Text PDFNeurol Genet
December 2024
From the Division of Neurology (A.H.T., S.-Y.L.), Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Programa de Pós-Graduação em Ciências Médicas da Universidade Federal do Rio Grande do Sul (P.S.-A.), Clínica Santa María, Santiago, Chile; Departamento de Farmacologia (A.F.S.S.), Universidade Federal do Rio Grande do Sul; Serviço de Neurologia (A.F.S.S.), Hospital de Clínicas de Porto Alegre, Brazil; Institute of Neurogenetics (H.M., M.L.D., C.K.), University of Lübeck, Germany; Department of Biomedical Science (A.A.-A.), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; The Michael J. Fox Foundation for Parkinson's Research (J.S., B.F.), New York; Department of Medical and Molecular Genetics (C.E.W.), Indiana University, Indianapolis; Department of Neuroscience and Brain Health (M.L.D.), Metropolitan Medical Center, Manila, Philippines; Centre for Preventive Neurology (S.D., M.T.P., A.J.N.), Wolfson Institute of Population Health, Queen Mary University of London, United Kingdom; Unidad de Trastornos del Movimiento (M.T.P.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Laboratory of Neurogenetics (M.B.M.), National Institute on Aging, National Institutes of Health, Bethesda, MD; Department of Clinical and Movement Neurosciences (M.B.M., H.R.M.), UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology (R.N.A.), Columbia University Irving Medical Center, New York; Movement Disorders Division (R.N.A.), Neurological Institute, Tel Aviv Sourasky Medical Center and Tel Aviv School of Medicine, Tel Aviv University, Israel; Molecular Medicine Laboratory and Neurology Department (K.R.K.), Concord Clinical School, Concord Repatriation General Hospital, The University of Sydney; Translational Neurogenomics Group (K.R.K.), Genomic and Inherited Disease Program, Garvan Institute of Medical Research; and St Vincent's Healthcare Campus (K.R.K.), Faculty of Medicine, UNSW Sydney, Darlinghurst, New South Wales, Australia.
Background And Objectives: In the era of precision medicine, genetic test results have become increasingly relevant in the care of patients with Parkinson disease (PD). While large research consortia are performing widespread research genetic testing to accelerate discoveries, debate continues about whether, and to what extent, the results should be returned to patients. Ethically, it is imperative to keep participants informed, especially when findings are potentially actionable.
View Article and Find Full Text PDFAm J Cancer Res
December 2024
Laboratory of Translational Oncology and Experimental Cancer Therapeutics, The Warren Alpert Medical School, Brown University Providence, RI 02903, USA.
Androgen receptor (AR) signaling is a target in prostate cancer therapy and can be treated with non-steroidal anti-androgens (NSAA) including enzalutamide, and apalutamide for patients with advanced disease. Metastatic castration-resistant prostate cancer (mCPRC) develop resistance becomes refractory to therapy limiting patient overall survival. Darolutamide is a novel next-generation androgen receptor-signaling inhibitor that is FDA approved for non-metastatic castration resistant prostate cancer (nmCRPC).
View Article and Find Full Text PDFJ Pharm Policy Pract
January 2025
College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates.
Objective: This pilot study evaluated the professional self-actualisation (PSA) of pharmacists in the United Arab Emirates (UAE) across various practice settings.
Methods: Our study was conducted in the UAE from February to May 2024 and targeted pharmacists in hospitals, community pharmacies, industry, and academia. A PSA questionnaire was developed using validated instruments and expert input, and included items on professional fulfilment (PF), societal acceptance (SA), work environment (WE), autonomy and professional opportunities (APO), involvement in professional advocacy (IPA), and the impact of work on personal relationships (IWPR).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!